Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case

被引：0
|
作者：
Gridelli, C. [1 ]
Rossi, A. [1 ]
Maione, P. [1 ]
Ferrara, C. [1 ]
Del Gaizo, F. [1 ]
Nicolella, D. [1 ]
Guerriero, C. [1 ]
Colantuoni, G. [1 ]
机构：
[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy
来源：
TARGETED ONCOLOGY | 2006年 / 1卷 / 01期
关键词：
Erlotinib; NSCLC; Elderly;
D O I：
10.1007/s11523-005-0004-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Erlotinib is a small molecule that selectively inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity. It demonstrated single-agent activity in patients with non-small cell lung cancer (NSCLC). Single-agent chemotherapy is the standard treatment of advanced NSCLC elderly patients. We report a case of a partial response in a 76-year-old never-smoker female affected by advanced lung adenocarcinoma refractory to first- and second-line chemotherapy.
引用
收藏
页码：56 / 58
页数：3
相关论文
共 50 条
  • [1] Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case
    C. Gridelli
    A. Rossi
    P. Maione
    C. Ferrara
    F. Del Gaizo
    D. Nicolella
    C. Guerriero
    G. Colantuoni
    [J]. Targeted Oncology, 2006, 1 : 56 - 58
  • [2] Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
    Zhou, Songwen
    Ren, Shengxiang
    Yan, Lianghua
    Zhang, Ling
    Tang, Liang
    Zhang, Jie
    Zhou, Caicun
    [J]. RESPIROLOGY, 2009, 14 (05) : 709 - 715
  • [3] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [4] Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
    Karaca, Halit
    Geredeli, Caglayan
    Kaplan, M. Ali
    Demirci, Umut
    Alici, Suleyman
    Artac, Mehmet
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    Balakan, Ozan
    Arpaci, Erkan
    Budakoglu, Burcin
    Uncu, Dogan
    Guler, Tunc
    Berk, Veil
    Ozkan, Metin
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (01): : 1 - 6
  • [5] Erlotinib in previously treated non small cell lung cancer
    Krause, M
    Baumann, M
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 (01) : 55 - 57
  • [6] ERLOTINIB FOR CHINESE ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Wang, H-P
    Li, Z.
    Wang, M-Z
    Yi, X.
    [J]. RESPIROLOGY, 2011, 16 : 172 - 172
  • [7] Initial safety and efficacy results of erlotinib in previously treated patients with advanced non-small cell lung cancer
    Zhou, S.
    Zhou, C.
    Yan, L.
    Xu, Q.
    Xu, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
    Marco Platania
    Francesco Agustoni
    Barbara Formisano
    Milena Vitali
    Monika Ducceschi
    Filippo Pietrantonio
    Nicoletta Zilembo
    Francesco Gelsomino
    Sara Pusceddu
    Roberto Buzzoni
    [J]. Targeted Oncology, 2011, 6 : 181 - 186
  • [9] Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
    Platania, Marco
    Agustoni, Francesco
    Formisano, Barbara
    Vitali, Milena
    Ducceschi, Monika
    Pietrantonio, Filippo
    Zilembo, Nicoletta
    Gelsomino, Francesco
    Pusceddu, Sara
    Buzzoni, Roberto
    [J]. TARGETED ONCOLOGY, 2011, 6 (03) : 181 - 186
  • [10] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 123 - 132
12345